MedPath

Acupuncture for the prevention of chronic migraine attacks

Not Applicable
Completed
Conditions
Chronic migraine (CM)
Nervous System Diseases
Registration Number
ISRCTN13563102
Lead Sponsor
Beijing Hospital of Traditional Chinese Medicine
Brief Summary

2018 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/29858418 protocol (added 13/05/2019) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38860524/ (added 25/06/2024)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
60
Inclusion Criteria

1. Diagnosed as chronic migraine according to the diagnostic criteria specified by the International Classification of Headache Disorders(International Classification of Headache Disorders-Third edition (beta version) [ICHD-?ß])
2. Aged between 18 and 65 years old
3. No prophylaxis treatments with acupuncture or drugs in the past 3 months
4. Written informed consent provided

Exclusion Criteria

1. Tension-type headache, cluster headache, and other primary headaches
2. Relatively severe systemic diseases(cardiovascular disease, acute infectious disease, hematopathy,endocrinopathy, allergy, and methysis)
3. Headache caused by otorhinolaryngology diseases or intracranial pathological changes
4. Secondary headache and other neurological diseases
5. Pregnancy, lactation, or insufficient contraception

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Monthly number of headache days (any intensity) is measured using the headache diary at baseline period (4 weeks before the beginning of treatment) and 12 weeks.
Secondary Outcome Measures
NameTimeMethod
1. Number of days with acute headache medications is measured using headache diary at baseline period (4 weeks before the beginning of treatment) and 12 weeks.<br>2. Migraine Disability is measured using the MIDAS score at baseline, 12 weeks, and 24 weeks.<br>3. Migraine-Specific Quality-of-Life Questionnaire/Headache impact test measured using the MSQ/HIT6 questionnaire at baseline, 12 weeks, and 24 weeks.<br>4. Anxiety is measured using the STAI/BDI-II questionnaires at baseline, 12 weeks, and 24 weeks.
© Copyright 2025. All Rights Reserved by MedPath